Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
John R. Wingard(University of Florida Health), Kieren A. Marr(Freedom to Live), Javier Bolaños‐Meade(Johns Hopkins University), J. Martin Brown(Palo Alto University), Edward A. Stadtmauer(University of Pennsylvania), Helen Leather(University of Florida), Michael Boeckh(Fred Hutch Cancer Center), Joanne Kurtzberg(Duke University), Adam Mendizabal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), John F. DiPersio(Washington University in St. Louis), Thomas J. Walsh(Cornell University), Iris D. Gersten(Emmes (United States)), Richard T. Maziarz(Oregon Health & Science University), Lindsey R. Baden(Brigham and Women's Hospital), Dennis L. Confer(National Marrow Donor Program), Trudy N. Small(Memorial Sloan Kettering Cancer Center), Shelly L. Carter(Emmes (United States))
Cited by 477
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
|Clinical Infectious Diseases|2005|3k